Angiotensin I

Biosynthesis

Angiotensin I is generated through proteolytic cleavage of the N-terminal leucine residue from angiotensinogen, a 453-amino acid glycoprotein produced constitutively by the liver. This conversion is catalyzed by renin, an aspartyl protease secreted by juxtaglomerular cells of the kidney in response to reduced renal perfusion pressure, sympathetic stimulation, and decreased sodium delivery to the macula densa. The resulting decapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) possesses minimal intrinsic biological activity but serves as the essential precursor for angiotensin II generation.

The Renin-Angiotensin Cascade

Angiotensin I functions as the obligate substrate for angiotensin-converting enzyme (ACE), a zinc-dependent dipeptidyl carboxypeptidase located predominantly on the pulmonary vascular endothelium. ACE cleaves the C-terminal dipeptide His-Leu from angiotensin I to produce the octapeptide angiotensin II. Additionally, ACE degrades bradykinin, contributing to the dual pressor and cardioprotective effects observed with ACE inhibitor therapy. Alternative processing pathways include chymase-mediated conversion in cardiac and vascular tissues, which accounts for the tissue-specific angiotensin II generation that persists despite systemic ACE inhibition.

Physiological Context

The generation of angiotensin I represents the rate-limiting step in the classical renin-angiotensin system. Plasma renin activity, measured by the rate of angiotensin I formation in vitro, serves as a clinical biomarker for renin-angiotensin system activation. Renin release is regulated by three principal mechanisms: intrarenal baroreceptor sensing of afferent arteriolar pressure, macula densa sodium-chloride sensing, and beta-1 adrenergic stimulation from renal sympathetic nerves.

Clinical Significance

While angiotensin I itself lacks direct vasoactive properties, its plasma concentration reflects the activation state of the renin-angiotensin system and is used diagnostically in the workup of renovascular hypertension and primary aldosteronism. The identification of angiotensin I as the ACE substrate led directly to the development of captopril and subsequent ACE inhibitors, which revolutionized the treatment of hypertension, heart failure, and diabetic nephropathy. Direct renin inhibitors such as aliskiren target the step preceding angiotensin I formation.

References

1. Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. Journal of Experimental Medicine. 1956;103:295-299.
2. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. Hypertension. 1991;17:895-901.
3. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of Managed Care Pharmacy. 2007;13:9-20.